CN1297657C - Pseudomonas aeruginosa mannose sensitive haemagglutination pilus strain - Google Patents
Pseudomonas aeruginosa mannose sensitive haemagglutination pilus strain Download PDFInfo
- Publication number
- CN1297657C CN1297657C CNB200510059850XA CN200510059850A CN1297657C CN 1297657 C CN1297657 C CN 1297657C CN B200510059850X A CNB200510059850X A CN B200510059850XA CN 200510059850 A CN200510059850 A CN 200510059850A CN 1297657 C CN1297657 C CN 1297657C
- Authority
- CN
- China
- Prior art keywords
- pseudomonas aeruginosa
- pilus
- strain
- mannose
- mannose sensitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000589517 Pseudomonas aeruginosa Species 0.000 title claims abstract description 163
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 title claims abstract description 147
- 230000035931 haemagglutination Effects 0.000 title claims abstract description 144
- 241001076388 Fimbria Species 0.000 claims description 12
- 238000000034 method Methods 0.000 abstract description 18
- 238000012258 culturing Methods 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 65
- 230000001580 bacterial effect Effects 0.000 description 47
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 35
- 238000012360 testing method Methods 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 231100000419 toxicity Toxicity 0.000 description 15
- 230000001988 toxicity Effects 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- 241000589516 Pseudomonas Species 0.000 description 13
- 210000003495 flagella Anatomy 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000243198 Peritrichia Species 0.000 description 8
- 210000002421 cell wall Anatomy 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 241000193830 Bacillus <bacterium> Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000014347 soups Nutrition 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000001018 virulence Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- YNCMLFHHXWETLD-UHFFFAOYSA-N pyocyanin Chemical compound CN1C2=CC=CC=C2N=C2C1=CC=CC2=O YNCMLFHHXWETLD-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000010065 bacterial adhesion Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000002955 immunomodulating agent Substances 0.000 description 5
- 229940121354 immunomodulator Drugs 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 4
- 230000002924 anti-infective effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 230000002584 immunomodulator Effects 0.000 description 4
- 230000007365 immunoregulation Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010040721 Flagellin Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 241000588769 Proteus <enterobacteria> Species 0.000 description 3
- 241000190932 Rhodopseudomonas Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010082340 Arginine deiminase Proteins 0.000 description 2
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 2
- 241000588923 Citrobacter Species 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 108010000916 Fimbriae Proteins Proteins 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 235000002710 Ilex cornuta Nutrition 0.000 description 2
- 241001310146 Ilex cornuta Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000009871 tenuigenin Substances 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 241000448435 Acalypha australis Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000605721 Dichelobacter nodosus Species 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 241000399350 Nitrolancea hollandica Lb Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000947836 Pseudomonadaceae Species 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 241000545442 Radix Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- MWBPRDONLNQCFV-UHFFFAOYSA-N Tri-allate Chemical compound CC(C)N(C(C)C)C(=O)SCC(Cl)=C(Cl)Cl MWBPRDONLNQCFV-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010048241 acetamidase Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- GZCGUPFRVQAUEE-VANKVMQKSA-N aldehydo-L-glucose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-VANKVMQKSA-N 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VOAXAOULFRTTAM-UHFFFAOYSA-N chloroform phenol Chemical compound C1(=CC=CC=C1)O.C(Cl)(Cl)Cl.C1(=CC=CC=C1)O.C1(=CC=CC=C1)O VOAXAOULFRTTAM-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010008385 glycolipid receptor Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- KELXKDDAALYTDI-BTVCFUMJSA-N nitric acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound O[N+]([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O KELXKDDAALYTDI-BTVCFUMJSA-N 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000997 thin albumen Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
The mycology feature | Pseudomonas aeruginosa strain of the present invention | Non-pseudomonas aeruginosa mannose sensitive haemagglutination pilus strain (is example with intestinal bacteria) |
Form | Gram negative bacillus end flagellum | The all flagellums of gram negative bacillus |
Power | The semi-solid top of positive (see figure 5) presents muddiness | Positive semi-solid top presents muddiness |
Oxidase test | Positive (see figure 3) | Negative |
The dull and stereotyped king A of pigment substratum | Verdigris pigment (see figure 4) | Non-pigment |
Glucose oxidase | Positive nonfermented | Negative fermentation (producing sour aerogenesis) |
The maltose oxidation | Not oxidation nonfermented | Fermentation (producing sour aerogenesis) |
The wood sugar oxidation | Positive nonfermented | Negative fermentation (producing sour aerogenesis) |
On Chinese holly wood-rimmed acid substratum | Growth | Do not grow |
Methionin decarboxylation acid test | Negative | ?- |
The arginine dihydrolase test | Positive | ?- |
Ornithine decarboxylase | Negative | ?- |
In 42 ℃ of brain heart infusion agars | Growth | Do not grow |
Serological test (Chengdu institute of Biological Products blood grouping serum) | IV type Pseudomonas aeruginosa | Do not react |
The mycology feature | Pseudomonas aeruginosa mannose sensitive haemagglutination pilus strain of the present invention | The non-mannose sensitive haemagglutination pilus strain of Pseudomonas aeruginosa | The relevant document of judgment standard |
Form | Many very thin and upright and outspoken pili (referring to Fig. 2) are arranged around the thalline | No mannose sensitive haemagglutination pilus | Electron microscope observation |
The mannose sensitive haemagglutination test | Positive (see figure 6) | Negative | Dalian Medical College's journal 1985,7 (1): 1-3 |
Flat-plate bacterial colony adheres to the red corpuscle test | Positive | Negative | The opticmicroscope low power is observed (10 * 10) |
Saccharomycetic direct agglutination test | The MS blood clotting positive | MS blood clotting feminine gender | Opticmicroscope (1000X) |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510059850XA CN1297657C (en) | 2005-03-31 | 2005-03-31 | Pseudomonas aeruginosa mannose sensitive haemagglutination pilus strain |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510059850XA CN1297657C (en) | 2005-03-31 | 2005-03-31 | Pseudomonas aeruginosa mannose sensitive haemagglutination pilus strain |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1670186A CN1670186A (en) | 2005-09-21 |
CN1297657C true CN1297657C (en) | 2007-01-31 |
Family
ID=35041626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200510059850XA Active CN1297657C (en) | 2005-03-31 | 2005-03-31 | Pseudomonas aeruginosa mannose sensitive haemagglutination pilus strain |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1297657C (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101880640B (en) * | 2010-02-09 | 2013-05-29 | 北京万特尔生物制药有限公司 | Klebsiella pneumoniae (Mannose-sensitive hemagglutination) pilus strain |
CN101914463B (en) * | 2010-02-09 | 2012-09-05 | 北京万特尔生物制药有限公司 | Proteus vulgaris (mannose-sensitive hemagglutination) piliated strain |
WO2013004020A1 (en) * | 2011-07-07 | 2013-01-10 | 深圳市宝舜泰生物医药股份有限公司 | Pseudomonas aeruginosa (pa-msha) strain igy and preparation method and use thereof |
CN103690941B (en) * | 2013-12-30 | 2016-03-23 | 北京万特尔生物制药有限公司 | A kind of Pseudomonas aeruginosa MSHA pilus strain tumor vaccine and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1090602A (en) * | 1993-02-06 | 1994-08-10 | 牟希亚 | Pseudomonos aeruginosa MSHA fimbria strain and foundation thereof |
-
2005
- 2005-03-31 CN CNB200510059850XA patent/CN1297657C/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1090602A (en) * | 1993-02-06 | 1994-08-10 | 牟希亚 | Pseudomonos aeruginosa MSHA fimbria strain and foundation thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1670186A (en) | 2005-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109576180B (en) | Rhodococcus ruber and application thereof as immunologic adjuvant in preparation of vaccine | |
Potter et al. | Decreased shedding of Escherichia coli O157: H7 by cattle following vaccination with type III secreted proteins | |
CN109337841B (en) | Bacillus subtilis BYS2 with efficient antibacterial performance | |
CN111269865B (en) | Brevibacillus laterosporus strain S62-9 and application thereof | |
CN112029696B (en) | Edwardsiella piscicola derived from turbot and application thereof | |
JP6833418B2 (en) | Lipopolysaccharide, lipopolysaccharide production method and lipopolysaccharide formulation | |
CN1297657C (en) | Pseudomonas aeruginosa mannose sensitive haemagglutination pilus strain | |
JP3601602B2 (en) | Non-toxic microorganisms and their use: Salmonella | |
Das et al. | Distribution of multi-virulence factors among Aeromonas spp. isolated from diseased Xiphophorus hellerii | |
CN108865931B (en) | Bacillus and application thereof | |
CN103436461A (en) | Novel lactic acid bacteria and immune reaction regulation uses thereof | |
CN1777670A (en) | New strains of bifidobacterium having the ability to produce glutamine | |
CN105695370B (en) | Clostridium butyricum and culture method and application thereof | |
CN106389475B (en) | Bacteroides fragilis is preventing and/or is treating the application in meningitis | |
CN105031635B (en) | A kind of preparation method and applications of S. pullonum inactivated vaccine | |
CN110295134A (en) | A kind of building and its application of surface display c-type perfringens alpha, β toxin protein recombinant plant lactobacillus | |
CN103602637A (en) | Vaccine strain for mycoplasma pneumonia of swine | |
CN107217013B (en) | Deinococcus T1R5 and application thereof in radiation protection | |
CN103266076B (en) | Space-induced efficient bifidobacterium bifidum and application thereof as well as preparation method of capsule preparation of space-induced efficient bifidobacterium bifidum | |
CN101829321A (en) | Vaccine for preventing red head disease of Pseudobagrus fulvidraco | |
US20020114794A1 (en) | Staphylococcus aureus culture and preparation thereof | |
CN1857332A (en) | Selenium-rich hedgehog fungus extract preparation for treating colitis, gastritis and stomach cancer and its preparing process | |
CN113930367A (en) | Lactic acid bacteria with cholesterol-reducing performance and application thereof | |
CN103266077B (en) | Space-induced efficient bifidobacterium longum, application thereof, and preparation method of capsule preparation thereof | |
KR101210082B1 (en) | Vaccine composition for swine polyserositis and manufacturing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing million Biotechnology Co., Ltd. Assignor: Mou Xiya Contract fulfillment period: 2007.3.1 to 2013.2.28 contract change Contract record no.: 2008110000149 Denomination of invention: Pseudomonas aeruginosa mannose sensitive haemagglutination pilus strain Granted publication date: 20070131 License type: Exclusive license Record date: 2008.12.2 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.3.1 TO 2013.2.28; CHANGE OF CONTRACT Name of requester: BEIJING WANTEER BIOISYSTECH CO., LTD. Effective date: 20081202 |
|
ASS | Succession or assignment of patent right |
Owner name: BEIJING WANTEER BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: MOU XIYA Effective date: 20090515 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090515 Address after: Beijing Yanqi Industrial Development Zone in Huairou District Patentee after: BEIJING WANTER BIO-PHARMACEUTICAL CO., LTD. Address before: Room 101, No. 101, Southwest Road, Shahekou District, Dalian, Liaoning Patentee before: Mou Xiya |